Fate Therapeutics, Inc. (FATE)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Fate Therapeutics topped expectations on EPS in the third fiscal quarter of 2026, and based on preliminary results reported November 5, 2026 it posted EPS of -$0.25 versus the -$0.27 estimate (difference $0.02), improving ~7% year over year from -$0.27 as the clinical-stage cellular immunotherapy developer continued to run its NK- and T-cell immuno-oncology pipeline without marketed-product revenue as a primary driver. Net loss narrowed to about $30.7 million, a ~5% year-over-year improvement from roughly $32.2 million a year ago, while operating loss was about $32.2 million for the quarter. Cash flow remained negative, with negative operating cash flow of roughly $27.9 million, reflecting ongoing R&D and operating spend tied to advancing programs such as FT516, FT596, FT538, and FT576. For the next period, consensus calls for EPS of -$0.28 on revenue of $1.1 million.
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing programmed cellular immunotherapies for cancer. The company works in the healthcare sector as a clinical-stage drug developer, with a pipeline centered on NK- and T-cell immuno-oncology programs rather than marketed products.
Today's Snapshot
FATE closed 2.9% higher at 1.05, outperforming a weaker sector. Fate Therapeutics outlined broader use for CAR T-cell therapy, which trains immune cells to fight cancer.
Trading Volume
Below 10d avg (2.4M)
1.8M
vs S&P 500 Today
Strong Outperformance
+3.20%
Updated: November 18, 2026 at 21:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.41 - $2.08Sell
- RSI (14)20.90Buy
- Stochastic %K (14, 3, 3)2.02Buy
- MACD Level (12, 26)-0.27Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.